Dependence on US FDA approvals for complex launches
Launch of high-value products like Rituximab biosimilar in the US depends on FDA approval, which is uncertain and could be delayed.
DRREDDY / Q2-FY25 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Revlimid revenue sustainability
Revenue from lenalidomide (Revlimid) is subject to confidential agreements and competitive pressures; management declined to provide specific guidance on future sales.
Currency risk in Russia
Russia business faces unfavorable forex movements; despite hedging, devaluation could impact reported revenues.
Impairment risk from supply chain issues
A product faced procurement constraints from contract manufacturers, leading to a ₹92 crore impairment; similar issues could affect other products.